This U.S. biotech stock is up 90% this year and will continue to soar, fund manager says
"We certainly think it's got significant growth in front of it," fund manager Dani Saurymper told Pro Talks of one diagnostics stock.
Source link
- Morgan Stanley says A.I. in China is at an inflection point — and names 3 stocks to play it
- Why Europe and Israel’s unicorns are producing the next generation of tech founders
